Shield Therapeutics Updates Voting Rights as Iron Drug Expansion Continues

Shield Therapeutics ( (GB:STX) ) has shared an announcement.

Shield Therapeutics plc, a London-listed specialty pharmaceutical company, focuses on iron deficiency treatment through its innovative oral iron therapy ACCRUFeR/FeRACCRU, marketed globally via a network of regional partners. With FDA approval, broad international licensing and patent coverage into the mid-2030s, the company is targeting a significant and growing market for iron deficiency and iron deficiency anemia treatments.

The company announced that its issued share capital now comprises 1,068,418,471 ordinary shares, each carrying equal voting rights and with no shares held in treasury. This updated share count sets the reference point shareholders must use to assess and report changes in their holdings under UK disclosure and transparency rules, clarifying Shield’s capital structure for investors and regulators.

By formally confirming its total voting rights, Shield reinforces transparency around its equity base at a time when it is pursuing commercial expansion of ACCRUFeR/FeRACCRU worldwide. The clarity on voting shares aids institutional and retail investors in monitoring significant positions while the company continues to build its presence in the global iron deficiency treatment market.

The most recent analyst rating on (GB:STX) stock is a Sell with a £9.50 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.

Spark’s Take on GB:STX Stock

According to Spark, TipRanks’ AI Analyst, GB:STX is a Neutral.

The overall stock score is primarily influenced by the company’s robust technical momentum and positive corporate events, which are offset by significant financial challenges and valuation concerns. The strong technical indicators and strategic corporate developments provide optimism, but financial instability remains a critical risk.

To see Spark’s full report on GB:STX stock, click here.

More about Shield Therapeutics

Shield Therapeutics plc is a commercial-stage specialty pharmaceutical group focused on treating iron deficiency, with or without anemia. Its lead product, the oral iron therapy ACCRUFeR/FeRACCRU (ferric maltol), is the first and only FDA-approved oral iron for ID/IDA and is commercialised via partners across the U.S., Europe, Canada and parts of Asia-Pacific, with patent protection into the mid-2030s.

The company has built its business around ACCRUFeR/FeRACCRU through an exclusive U.S. collaboration with Viatris and multiple international licensing deals. This positions Shield to capture a share of an estimated $2.3 billion U.S. market for iron deficiency treatments, where ACCRUFeR is currently the leading branded prescription oral iron product by volume, according to IQVIA data.

Average Trading Volume: 2,591,856

Technical Sentiment Signal: Buy

Current Market Cap: £104.1M

Learn more about STX stock on TipRanks’ Stock Analysis page.